

Rep. Waxman renews his request that the FDA investigate whether phenylephrine oral nasal decongestants are effective. In the ad, Schering-Plough announced that it will not reformulate Claritin-D, a pseudoephedrine-based oral nasal decongestant, to switch to phenylephrine.

Provisions in the 2006 reauthorization of the Patriot Act require that pseudoephedrine products be moved behind the counter, so Claritin-D will not be able to be sold over-the counter. Therefore, Schering's decision not to reformulate Clairitin-D strongly suggests that a study of phenylephrine's effectiveness that the company conducted and completed in 2006 may have raised significant questions about the effectiveness of phenylephrine.

### **Documents and Links**

- [Letter to FDA on Claritin D Advertisement](#)
- [Previous Letters to FDA Asking for Re-evaluation of Phenylephrine](#)
- [Claritin Newspaper Ad](#)